What molecule am I?
Baricitinib, a rheumatoid arthritis drug, is under development by Incyte (Wilmington, DE) and Eli Lilly (Indianapolis). It was approved for use under some conditions by the European Union in 2017 and by the US Food and Drug Administration in 2018. Its mechanism of action against rheumatoid arthritis is inhibition of janus kinase enzymes, specifically subtypes JAK1 and JAK2.
Because of current events, baricitinib may have a more urgent application. About a month ago, Justin Stebbing and colleagues at Imperial College London and the artificial intelligence drug discovery company BenevolentAI (London) reported that their AI software turned up an existing drug—baricitinib—that may limit the effects of COVID-19, the coronavirus that is rapidly spreading worldwide.
The researchers used available information about COVID-19 to identify the enzyme adaptor-associated protein kinase 1 (AAK1) as a possible coronavirus target. The AI software then canvassed known AAK1 inhibitors for possible leads to a COVID-19 drug. Baricitinib stood out for its strong affinity for the kinase and its low toxicity.
The authors believe that baricitinib may be able to reduce the ability of the virus to infect lung cells. But they cautioned that their findings should not be considered medical advice; rather, baricitinib could be a clue for other researchers to find treatments for the virus.
Baricitinib hazard information
|Hazard class*||Hazard statement|
|Acute toxicity, oral, category 4||H302—Harmful if swallowed.|
|Reproductive toxicity, category 1B||H360—May damage fertility or the unborn child|
|Specific target organ toxicity, repeated exposure, category 2||H373—May cause damage to organs through prolonged or repeated exposure|
Baricitinib fast facts
|CAS Reg. No.||1187594-09-7|
|Molar mass||371.42 g/mol|
|Appearance||White crystals or powder|
|Melting point||213–215 ºC|
|Water solubility||<1 g/L|
MOTW update: December 7, 2020
Baricitinib is a janus kinase inhibitor that initially showed promise against rheumatoid arthritis. This past February, researchers reported that it may limit the effects of COVID-19 by attacking a specific enzyme in the virus. On November 19, the US Food and Drug Administration issued an emergency use authorization for the combination and remdesivir (MOTW for April 6, 2020) “for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.”
Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.
Stay Ahead of the Chemistry Curve
Learn how ACS can help you stay ahead in the world of chemistry.